Early circulating strain of SARS-CoV-2 causes severe pneumonia distinct from that caused by variants of concern

Yusuke Matsumoto  
Tokyo Metropolitan Institute of Medical Science

Fumihiko Yasui  
Tokyo Metropolitan Institute of Medical Science

Akinori Endo  
Tokyo Metropolitan Institute of Medical Science

Takahiro Sanada  
Tokyo Metropolitan Institute of Medical Science

Tsubasa Munakata  
Tokyo Metropolitan Institute of Medical Science

Asako Takagi  
Tokyo Metropolitan Institute of Medical Science

Kenzaburo Yamaji  
Tokyo Metropolitan Institute of Medical Science

Naoki Yamamoto  
Tokyo Metropolitan Institute of Medical Science

Yasushi Saeki  
Tokyo Metropolitan Institute of Medical Science

Michinori Kohara (kohara-mc@igakuen.or.jp)  
Tokyo Metropolitan Institute of Medical Science

Research Article

Keywords:

Posted Date: January 26th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1267705/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

To analyze the molecular pathogenesis of SARS-CoV-2, a small animal model such as mice is needed: human ACE2, the receptor of SARS-CoV-2, needs to be expressed in the respiratory tract of mice. We conferred SARS-CoV-2 susceptibility in mice by using an adenoviral vector expressing hACE2 driven by an EF1α promoter with a leftward orientation. In this model, severe pneumonia like human COVID-19 was observed in SARS-CoV-2-infected mice, which was confirmed by dramatic infiltration of inflammatory cells in the lung with efficient viral replication. An early circulating strain of SARS-CoV-2 caused the most severe weight loss when compared to SARS-CoV-2 variants of concern, although histopathological findings, viral replication, and cytokine expression characteristics were comparable. We found that a distinct proteome of an early circulating strain infected lung characterized by elevated complement activation and blood coagulation, which were mild in other variants, can contribute to disease severity. Unraveling the specificity of early circulating SARS-CoV-2 strains is important in elucidating the origin of the pandemic.

Main Text

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently causing a worldwide pandemic. Development of animal models that recapitulate coronavirus disease 2019 (COVID-19) are essential for evaluating vaccines and antivirals, and for understanding the pathogenesis of the disease. Although several SARS-CoV-2 animal models have been described to date, such as monkeys, ferrets, and hamsters, mice are considered to be better suited for use as animal models given their small size, rapid breeding cycles, and well-characterized immunological background. However, due to the lack of the viral entry receptor, human angiotensin converting enzyme (hACE2), laboratory mouse strains are non-permissive to the circulating SARS-CoV-2 infection. Several groups have reported mice that either permanently or transiently express hACE2. There are three transgenic mouse models using different promoters to drive permanent hACE2 expression, including a universal cytomegalovirus (CMV) enhancer/beta-actin promoter, epithelial cell-specific promoter (K-18 or HFH4), and the endogenous mouse ACE2 promoter. Nevertheless, the production of hACE2 transgenic mice is time-consuming and their versatility is limited as they are restricted to a single genetic background. hACE2 expression in mice can be achieved rather quickly by adeno-associated virus (AAV)- or adenovirus type 5 (Ad5)-mediated transduction. SARS-CoV-2 replication in mice sensitized by AAV-hACE2 transduction appears to be lower than that reported in other mouse models. Transduction of mice with CMV promoter-driven hACE2-expressing Ad5 confers SARS-CoV-2 susceptibility, but only mild to moderate pulmonary pathogenesis has been induced by SARS-CoV-2 infection. The induction of an antiviral immune response to the adenovirus vector itself is supposed to have a negative effect on SARS-CoV-2 infection, which may inhibit severe disease in the mouse respiratory tract.

The commonly used CMV-driven transgene-expressing Ad5 vectors lack the intrinsic viral E1 gene that is essential for adenovirus growth, where a transgene can be inserted. When the expression unit was
inserted in the rightward orientation, a viral pIX gene located downstream of the inserted unit was co-expressed with the transgene, and a fusion protein consisting of the N-terminal part of transgene product was expressed. These pIX products may be one of the main causes of adenovirus-induced immune responses. Interestingly, the EF1α promoter did not activate the pIX promoter in this adenoviral vector\textsuperscript{17}. The EF1α promoter with a leftward orientation resulted in a reduced antiviral response and maintained prolonged transgene expression\textsuperscript{17}. Thus, we generated an adenoviral vector expressing hACE2 under the EF1α promoter with a leftward orientation (rAd5 pEF1α-hACE2-L) (Fig. 1a). We first examined whether intranasal administration of rAd5 pEF1α-hACE2-L affects the body weight of BALB/c mice, and found that administration at $5 \times 10^7$ or $2.5 \times 10^8$ focus forming units (FFU) per mouse did not cause any decrease in body weight (Fig. 1b). Next, BALB/c mice were intranasally administered with rAd5 pEF1α-hACE2-L at $1 \times 10^7$, $5 \times 10^7$ or $2.5 \times 10^8$ FFU/animal. Five days after administration, mice were further intranasally inoculated with an early circulating strain of SARS-CoV-2 isolated in Japan (originated from Wuhan; Wu-2020 strain) at $1 \times 10^5$ plaque forming units (PFU) per mouse (Fig. 1c). As a result, the $5 \times 10^5$ FFU rAd5/mouse group showed a marked reduction in body weight, which peaked at 5-6 days post-infection (dpi) with SARS-CoV-2 Wu-2020. Although the $2.5 \times 10^8$ FFU rAd5/mouse group showed weight loss until 4 dpi of SARS-CoV-2 infection, this group showed recovery of body weight after 5 dpi. The $1 \times 10^7$ FFU rAd5/mouse group showed a slight reduction of weight followed by rapid recovery. Therefore, we determined that $5 \times 10^7$ FFU rAd5/animal was the most suitable dose for assessing disease severity.

Comparison of low ($1 \times 10^4$ PFU/mouse) and high ($1 \times 10^5$ PFU/mouse) titers of SARS-CoV-2 infection demonstrated that weight loss was more apparent in the high-titer group, approximately 25% maximum (Fig. 1d). Dark red and brown lesions were observed on the surfaces of lungs infected with $1 \times 10^5$ PFU of SARS-CoV-2 at 7 dpi (Fig. 1e). Histopathologically, SARS-CoV-2 infected lungs showed evidence of severe pneumonia with profound infiltration of leukocytes, including macrophages, neutrophils and lymphocytes, in alveoli with thickened epithelium, hemorrhaging and improved blood coagulation (Fig. 1e).

Variants of concern (VOCs) have emerged showing evidence of altered virus characteristics\textsuperscript{18}. VOCs have been associated with increased transmissibility, evasion of immunity from infection and vaccination, and reduced susceptibility to antibody therapies\textsuperscript{19–21}. Large population studies have observed a significant trend toward increased mortality associated with B.1.1.7\textsuperscript{22,23}. We studied the pathogenesis of VOCs [QHN001 (B.1.1.7), TY7-501 (P.1) and TY8-612 (B.1.351)], which were clinically isolated in Tokyo. We first examined the growth characteristics of these VOCs and the Wu-2020 strain in Vero E6/TMPRSS2 cells\textsuperscript{24} at a multiplicity of infection (MOI) of 0.001, and found that the growth kinetics were almost comparable among strains (Fig. 2a). To analyze their replication in mouse lungs, we inoculated the rAd5 pEF1α-hACE2-L administered BALB/c mice with SARS-CoV-2 via the intranasal route. Viral replication in the lungs was examined by quantitative real-time RT-PCR (qRT-PCR) for the detection of SARS-CoV-2 genome, and by plaque assay using Vero E6/TMPRSS2 cells. A clear increase in viral replication was observed with a peak at 2 dpi in all strains (Fig. 2b and 2c), followed by a gradual decrease towards 7 dpi. The B.1.351 strain showed reduced genome copy numbers (significantly at 7 dpi), but other strains showed
comparable genome copy numbers throughout the course of infection. Macroscopically, in Wu-2020- and B.1.1.7 strain-infected lungs, multiple dark red and brown lesions appeared on the surfaces of all lung lobes from 4 to 7 dpi (Fig. 2d, arrows). In contrast, the discolored lesions were restricted to the upper left lobe in P.1- and B.1.1351 strain-infected lungs at 7 dpi. The loss of body weight in mice did not correspond to the extent of viral replication and lung lesions (Fig. 2e). The B.1.351 strain, an exception, showed less viral replication and lesions in the lungs, so the degree of weight loss was lower throughout the course of infection. Although viral replication was similar in the B.1.1.7 and P.1 strains, the appearance of lung lesions was more pronounced in B.1.1.7, however, weight loss was relatively more pronounced in P.1. Mice infected with all four strains continued to lose weight until 5 dpi, but mice infected with three VOCs began to recover thereafter. Though viral replication and the extent of lung lesions were comparable in B.1.1.7- and Wu-2020-infected mice, mice infected with Wu-2020 did not regain weight, resulting in significant weight loss at 7 dpi compared with mice infected with VOCs (Fig. 2e).

The histopathological analysis demonstrated that severe pneumonia with thickened alveolar walls, inflammatory cell infiltration, hemorrhaging, and thrombus formation was remarkable in the dark red and brown lesions of the lung (Fig. 3a, hematoxylin and eosin staining; HE). Even in areas where discoloration was not obvious macroscopically, thickened alveolar walls and mild infiltration of inflammatory cells were observed (Supplementary Fig. 1, HE). Immunohistochemistry using an antibody against SARS-CoV-2 nucleocapsid (N) protein showed that the viral antigen was present in the lung epithelial cells (Fig. 3a and supplementary Fig. 1). The viral antigen was stained most prominently at 2 dpi. Few viral antigens were found in lesions with remarkable cellular infiltration.

Next, we examined cytokine expression in the lung using a multiplex bead array. Inflammatory cytokine, such as IL-6, was significantly elevated in all strains compared to mock-infected animals (Fig. 3b). Furthermore, IL-1b, IFN-g, IL-12, MIP-1b, MIP-2, LIF, KC, IL-10, MCP-1, M-CSF, G-CSF, and GM-CSF were significantly elevated and VEGF was decreased, at least in a strain compared to mock-infected mice. In B.1.351-infected lungs, the expression of some cytokines, such as MIP2, LIF, and MCP-1, was relatively low compared to other strains. This is correlated with the manifestation of low viral replication and mild weight loss. For infection by other strains, there was no clear evidence of a relationship between cytokine levels and disease severity.

The clinical severity of COVID-19 is not always associated with increased levels of pro-inflammatory cytokines and other inflammation markers. To survey the molecules associated with disease severity, tandem mass tag (TMT) peptide labeling, combined with mass spectrometry (MS) quantitative proteomics in mouse lung at 7 dpi with SARS-CoV-2 was performed. The TMT-based quantitative proteomic method was approved previously for comparison of protein levels across multiple organs in human COVID-19 autopsy cases. TMTpro 12-plex MS revealed distinct lung proteomes associated with infection by SARS-CoV-2 strains (Fig. 4a and Supplementary Fig. 2a). Gene ontology (GO) enrichment analysis of significantly (p<0.05) up- and down-regulated (2-fold) proteins showed that the proteome of Wu-2020-infected lung was distinct from those of other variants (Fig. 4b). Immune response-related
factors, such as regulation of complement activation, immune effector process, as well as platelet degranulation and regulation of blood coagulation, were enriched in the proteins that changed significantly in the proteome of Wu-2020-infected lungs (Fig. 4b). In contrast, the proteomes of VOC-infected lungs were associated with structural organization, such as the development of extracellular structures and changes in matrix organization, as well as nuclear DNA replication. Up-regulation of proteins associated with complement activation, e.g., C3a anaphylatoxin chemotactic receptor, complement components and complement factors was prominent in Wu-2020-infected lungs (Fig. 4c). The complement system has been shown to be involved in the severity of human COVID-19\textsuperscript{27,28}. Up-regulation of proteins involved in platelet degranulation and blood coagulation, e.g., kininogen, fibronectin, plasminogen activator inhibitor-1, coagulation factor XII and plasma kallikrein, was also remarkable in Wu-2020-infected lung tissue (Fig. 4d and f). These factors are considered to work in concert and contribute to COVID-19 pneumonia via dysregulation of thrombus formation. Up-regulation of minichromosome maintenance complex component (MCM)2, 3, 4, 5, 6, and 7, which are related to nuclear DNA replication, was observed in SARS-CoV-2 infection, regardless of strain (Fig. 4g). MCM2-7 act as replicative DNA helicases that unwind the DNA duplex template as a hetero-hexameric complex\textsuperscript{29}. The involvement of the MCM family in immune responses against viral infection is still poorly characterized. However, MCM up-regulation is correlated with proliferation and maintenance of leukocytes\textsuperscript{30,31}, suggesting that the MCM family is involved in the activation of infiltrating cells in the COVID-19 pneumonia observed in lungs infected with all of the virus strains. Structural organization-related proteins, such as collagens, were down-regulated in VOC-infected lungs (Fig. 4e). Collagen deposition is a hallmark of lung fibrosis\textsuperscript{32} and has been confirmed in the lungs of COVID-19 patients\textsuperscript{33}. It is considered that collagen deposition may be correlated with mild disease onset based on the recovery of body weight in VOC-infected mice. Pathway analysis based on Wikipathways (https://www.wikipathways.org/index.php/WikiPathways) supports the enrichment of complement and coagulation cascades, as well as the blood-clotting cascade, in Wu-2020-infected lungs (Supplementary Fig. 4).

We established a system to recapitulate COVID-19-like pneumonia in mice infected with SARS-CoV-2 after inducing hACE2 with rAd5 pEF1α-hACE2-L. When rAd5 pEF1α-hACE2-L was used, there were few abnormalities in protein expression (Supplementary Fig. 2a), suggesting that this adenoviral vector has low cytotoxicity. Mice infected with the Wu-2020 strain developed diffuse pneumonia. Histopathologically, thickened alveolar walls, hemorrhaging, and infiltration of inflammatory cells were prominent. The SARS-CoV-2 N antigen was found in alveolar epithelial cells, not in the lesions infiltrated by inflammatory cells; rather, the antigen was concentrated in areas that retained relatively normal alveolar structure. These findings were consistent with human COVID-19 autopsy cases in early 2020\textsuperscript{34,35}.

SARS-CoV-2 Wu-2020, an early circulating strain, was shown to be highly pathogenic in mouse lung. The Wu-2020, B.1.1.7 and P.1 strains have comparable replication potentials in both Vero E6/TMPRSS2 cells and mouse lung (Fig. 2a-c). In addition, these strains induced a marked cytokine response (Fig. 3b), and
infection led to similar histopathological findings (Fig. 3a and Supplementary Fig. 1). However, there was a clear difference in the lung proteome (Fig. 4b) between the Wu-2020 strain, which induced prolonged weight loss, and the other strains, which induced weight loss followed by recovery (Fig. 2e). The findings showed that proteins involved in the complement system were elevated most markedly in cases of Wu-2020 infection (Fig. 4b and c). The release of proinflammatory complement peptides helps to recruit leukocytes to the lung and aids in the assembly of the terminal complex that damages vascular endothelium. Increased levels of complement fragments is related to disease severity in COVID-19 patients, which suggests that they are well suited for use as a marker for serious injury in Wu-2020-infected lung. The altered blood coagulation system, which is manifested by the up-regulation of thrombosis-associated proteins, such as tissue factor (TF), coagulation factor XII and plasma kallikrein (Fig. 4f), can also be involved in disease severity in Wu-2020-infected lungs. TF initiates the extrinsic coagulation pathway to form thrombin in response to tissue injury and inflammation. Coagulation factor XII is activated by polyphosphates released from platelets, and initiates an intrinsic coagulation cascade, which occurs with disease onset in acute respiratory distress syndrome. Factor XII also activates plasma kallikrein, thereby increasing the formation of the proinflammatory peptide bradykinin. Simultaneously, several inhibitory factors for complement activation, such as complement factor H and vitronectin (Fig. 4c), and for coagulation, such as plasminogen which activates fibrinolysis (Fig. 4d), were up-regulated in Wu-2020-infected lungs; these factors may play a role for prevention of excessive tissue injury. These results indicate that molecular events in pneumonia lesions are altered in ways that cannot be observed by morphological observation. Even in these cases, the lung damage associated with elevated proteins that are related with complement activation, platelet degranulation and blood coagulation may result in the manifestation of severe symptoms, such as unrecovered weight loss after Wu-2020 infection.

In this study, levels of pro-inflammatory cytokines could not be used as markers of disease severity. Rather, the findings showed that complement-related and blood coagulation factors may be key factors associated with COVID-19 severity. In addition, we observed 35-fold and 9-fold up-regulation of metallothioneine-2 (Mt2) and Mt1, respectively, in Wu-2020-infected lung (Supplementary Fig. 3). Mt1/2, which are potently induced by heavy metals, other sources of oxidative stress and cytokines, facilitate metal binding and detoxification. In response to GM-CSF, macrophages express Mts (Mt2 rather than Mt1), which are involved in antimicrobial responses and contribute to the production of reactive oxidative species. We observed a correlation between disease severity and Mt1/2 amount, suggesting that Mt1/2 may act as a marker for COVID-19 severity. Additionally, we identified other potential biomarkers that may be correlated with disease severity, including tenascin, membrane-spanning 4-domains subfamily A member 6C and stefin-1/3 (Supplementary Fig. 3), whose associations with COVID-19 have not been studied to date. Furthermore, abundance of the SARS-CoV-2 N protein in lungs infected with Wu-2020 was markedly higher than that in other strains (Supplementary Fig. 3). SARS-CoV-2 N protein has been shown to promote NLRP3 inflammasome activation, and it is possible that SARS-CoV-2 N protein remaining in the lung may stimulate excessive inflammation. The amount of residual SARS-CoV-2 N protein in lesions may also be indicative of lung injury. It is possible that a comparison of SARS-CoV-2
strains that exhibit different pathogenicity may reveal the existence of novel biomarkers for disease severity.

Intrinsic etiological differences in VOCs have not been demonstrated. Although the B.1.1.7, P1, and B.1.351 strains do not show increased pathogenicity in hamsters\textsuperscript{50–53} or rhesus macaques\textsuperscript{54}, B.1.1.7 and B.1.351 strains showed high pathogenicity in the K-18 hACE2 Tg mouse model\textsuperscript{55,56}. Our findings revealed that there is a difference in the manifestation of symptoms associated with SARS-CoV-2 strains, and that an early isolated strain was highly pathogenic in the lung. The major difference between our findings and previous studies is that the respiratory-specific pathogenesis of SARS-CoV-2 was recapitulated in the mouse model using rAd5 pEF1α-hACE2-L in this study. SARS-CoV-2 infection involves extra-respiratory manifestations, including cardiac, gastrointestinal, hepatic, renal, and neurological symptoms. Disease severity in K-18 mice infected with B.1.1.7 and B.1.351 strains may be due to these extra-respiratory symptoms, as shown by the presence of neurological pathogenesis\textsuperscript{57,58}. Comparative studies of human autopsy cases of each variant have not yet been performed. Some autopsy cases of patients infected with the B.1.1.7 and P1 strains revealed no significant morphological or histopathological differences compared to early circulating strains\textsuperscript{59,60}. However, our findings showed that the elevation of several potent biomarkers may affect lung pathogenesis. Understanding the overall differences in an organ's proteome can help to unravel the pathology of emerging variants. With the accumulation of autopsy cases infected with VOCs, these changes in pathologies will be revealed.

In conclusion, we demonstrated that an early circulating SARS-CoV-2 specifically induces the manifestation of severe symptoms and is associated with dramatically altered host responses. How pathogenicity was transformed from the initial strains to that observed in the VOCs needs to be elucidated. Detailed analyses of the pathogenicity of the early circulating strains will lead to a better understanding of the origin of the pandemic.

\section*{Declarations}

\subsection*{Acknowledgements}

This work was supported in part by a grant from the Japan Agency for Medical Research and Development (AMED) (Grant No. 20nk0101615h001), the Takeda Science Foundation, and the Tokyo Metropolitan Government, Japan. We thank Drs. Masayuki Saijo and Mutsuyo Takayama-Ito, and Masaaki Sato of Department of Virology 1, National Institute of Infectious Diseases, Japan for gifting us viruses. We thank Dr. Yuko Tokunaga, Masahiko Higa, Aya Koseki and Sayaka Ono for assistance with experiments.

\subsection*{Competing interests}

The authors declare no competing financial or non-financial interests.

\subsection*{Author Contributions}
Y.M., F.Y. and M.K. conceived, designed, coordinated and performed the study, contributed to data interpretation, data presentation and manuscript writing. T.S., T.M., K.Y. and N.Y. assisted with the animal experiments. N.Y. assisted with the qRT-PCR experiments for quantitation of the viral genome. A.T. assisted with the generation of the adenoviral vector. Y.M., A.E., K.Y. and Y.S. performed proteome analyses and contributed to data presentation.

**Methods**

**Ethics statement**

All experiments using mice were approved by the Tokyo Metropolitan Institute of Medical Science Animal Experiment Committee and were performed in accordance with the animal experimentation guidelines of the Tokyo Metropolitan Institute of Medical Science.

**Cells and viruses**

Vero E6/TMPRSS2 cells, which constitutively express human TMPRSS2\textsuperscript{24}, and human embryonic kidney 293 (HEK293) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin, and G-418 (1 mg/mL, only in VeroE6/TMPRSS2 cells). All cells were cultured at 37°C in 5% CO\textsubscript{2}.

SARS-CoV-2 early circulating strain (TY/WK-521) and VOCs [QHN001 (B.1.1.7, alpha strain), TY7-501 (P.1, gamma strain) and TY8-612 (B.1.351, beta strain)] were obtained from the National Institute of Infectious Diseases, Japan.

**Generation of rAd5 pEF1\textalpha-hACE2-L**

E1- and E3-deleted adenovirus derived from human adenovirus type 5 encoding expression units with a leftward orientation were used in this study, as described previously\textsuperscript{17,61}. The hACE2 gene was cloned in the antisense orientation into pAxCAwtit2, the adenoviral cosmid vector that contains the left end of adenovirus type 5 with the E1 region substituted with an expression cassette containing the EF1\textalpha promoter and a multicloning site using an Adenovirus Dual Expression Kit (Takara Bio, Tokyo, Japan). The rAd5 pEF1\textalpha-hACE2-L was generated by transfecting pAxCAwtit2 encoding hACE2 into HEK293 cells by using CalPhos Mammalian Transfection Kit (Takara Bio). The rAd5 pEF1\textalpha-hACE2-L were purified using two rounds of cesium chloride gradient centrifugation, and the titers of the concentrated and purified virus stocks were determined using HEK293 cells and an Adeno-X Rapid Titer Kit (Takara Bio) according to the manufacturer’s instructions.

**Plaque formation assay**

Vero E6/TMPRSS2 cells in six-well plates were washed with DMED-GlutaMAX, and inoculated with serially diluted SARS-CoV-2, and incubated at 37°C for 60 min with rocking every 15 min. After removing
the viruses, cells were washed with DMEM-GlutaMAX and overlaid with agarose medium. After incubation of cells at 37°C for 2 days, the plaques were visualized with crystal violet staining and counted.

**Mouse study**

Specific pathogen-free 7-8-week old female BALB/c mice (Japan SLC, Hamamatsu, Japan) were intranasally inoculated with 1, 2.5 or 5´10^7 FFU rAd5 pEF1α-hACE2-L/mouse in a 50 µL volume. Five days after inoculation, SARS-CoV-2 was intranasally inoculated in a 50 µL volume. Prior to inoculation, mice were anesthetized by intraperitoneal administration of ketamine-xylazine mixture.

**Viral RNA quantification**

The left lung lobe from each mouse was homogenized in nine volumes of Leibovitz's L-15 medium (Thermo Fisher Scientific, Waltham, MA, USA) using a Multi-Bead Shocker (Yasui Kikai, Osaka, Japan). Total RNA samples were extracted from 50 µL of the supernatant of lung homogenates using Isogen LS (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. Fifty nanograms of total RNA was used for quantitating the SARS-CoV-2 genome. Viral RNA was quantified using a 1-step reverse transcription qRT-PCR, as described previously^62^. Viral loads were calculated as copies per 1 µg of total RNA.

**Multiple cytokine expression analyses**

The left lung lobes were lysed in lysis buffer (1% Triton-X100, 20 mM EDTA, 50 mM Tris-Cl pH 7.5, 150 mM NaCl) containing cOmplete protease inhibitor (Sigma Aldrich, MO, USA), and were assayed using the Bio-plex Suspension Array System, which utilizes Luminex-based technology. Mouse Cytokine/Chemokine Magnetic Bead Panel (32-plex) was used according to the manufacturer's instructions (Merck KGaA, Darmstadt, Germany).

**Immunohistochemistry**

The mice lungs were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at a thickness of 4-μm, stained with HE, and subjected to routine histological examination. Paraffin block sections were also used for staining of the SARS-CoV-2 N protein. Antigen retrieval was performed by autoclaving sections in 10 mM citrate buffer (pH 6.0) for 10 min, and then the sections were immersed in 0.3% hydrogen peroxide in methanol at room temperature for 30 min to inactivate endogenous peroxidase. The sections were blocked with BlockAce (DS Pharma Biomedical, Osaka, Japan) for 15 min, and incubated overnight at 4°C with 2 mg/mL of rabbit anti-SARS-CoV-2 N protein monoclonal antibody [HL344] (GenTex, Inc., CA, USA). Secondary labeling was performed by incubation at RT for 30 min with EnVision+ System-HRP labeled Polymer Anti-Rabbit (Dako Denmark A/S, Glostrup, Denmark), followed by color development with ImmPACT DAB Peroxidase Substrate (Vector Laboratories, Burlingame, CA, USA) at RT for 10 min. Nuclear staining was performed with hematoxylin solution.

**TMTpro 12-plex MS analysis**
Lysates extracted from left lung lobes were processed and digested by using an EasyPep Mini MS Sample Prep kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Three mouse lungs were pooled, and 25 µg of peptides from each sample were labeled with 0.25 mg of TMTpro mass tag labeling reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol. After TMT labeling, the 8 sample channels were combined in equal proportions, dried using a speed-vac, and resuspended in 0.1% TFA. Samples were fractionated into 8 fractions using High pH Reversed-Phase Peptide Fractionation Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. One microgram of peptide from each fraction was analyzed by LC-MS/MS on an EASY-nLC 1200-connected Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific) equipped with an FAIMS-Pro ion mobility interface (Thermo Fisher Scientific). Peptides were separated on an analytical column (C18, 1.6 µm particle size ´ 75 µm diameter ´ 250 mm, Ion Opticks) using 4-hr gradients (0% to 28% acetonitrile over 240 min) with a constant flow of 300 nL/min. Peptide ionization was performed using a Nanospray Flex Ion Source (Thermo Fisher Scientific). FAIMS-Pro was set to three phases (-40, -60, and -80 CV) and a ‘1 sec cycle for a phase’ data-dependent acquisition method was used where the most intense ions in every 1 sec were selected for MS/MS fragmentation by HCD. MS raw files were analyzed using a Sequest HT search program in Proteome Discoverer 2.4 (Thermo Fisher Scientific). MS/MS spectra were searched against the SwissProt reviewed mouse reference proteome (UniProt). TMTpro-based protein quantification was performed using the Reporter Ions Quantier node in Proteome Discoverer 2.4.

**Statistical analysis**

Statistical analyses were performed with Prism software (version 9.1.2; GraphPad, San Diego, CA, USA). Statistical significance was assigned when p values were <0.05. Inferential statistical analysis was performed by one-way analysis of variance (ANOVA), followed by Tukey’s test.

**References**

1. Rockx B. *et al.* Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **368**, 1012–1015 (2020).

2. Blanco-Melo, D. *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* **181**, 1036-1045.e9 (2020).

3. Chan JF. *et al.* Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. *Clinical Infectious Diseases* **71**, 2428–2446 (2020).

4. Kim, Y.-I. *et al.* Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host Microbe* **27**, 704-709.e2 (2020).

5. Yu, P. *et al.* Age-related rhesus macaque models of COVID-19. *Anim. Models Exp. Med.* **3**, 93–97 (2020).

6. Imai M. *et al.* Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc Natl Acad Sci U S A.* **117**, 16587–16595 (2020).
7. Markus H. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8. (2020).
8. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
9. Li, J.-Y. et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. *Microbes Infect.* **22**, 80–85 (2020).
10. Bao L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* **583**, 830–833 (2020).
11. Winkler ES. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nat. Immunol.* **21**, 1327–1335 (2020).
12. Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. *Cell* **182**, 50-58.e8 (2020).
13. Shi-Hui Sun. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. *Cell Host & Microbe* **28**, 124-133.e4. (2020).
14. Israelow B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. *J Exp Med*, **217**, e20201241 (2020).
15. Hassan, A. O. et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. *Cell* **182**, 744-753.e4 (2020).
16. Sun, J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. *Cell* **182**, 734-743.e5 (2020).
17. Nakai, M. et al. Expression of pIX Gene Induced by Transgene Promoter: Possible Cause of Host Immune Response in First-Generation Adenoviral Vectors. *Human Gene Therapy* **18**, 925–36 (2007).
18. Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat. Rev. Microbiol.* **19**, 409–424 (2021).
19. Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **593**, 130–135 (2021).
20. Gupta, R. K. Will SARS-CoV-2 variants of concern affect the promise of vaccines? *Nat. Rev. Immunol.* **21**, 340–341 (2021).
21. Campbell, F. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill* **26**, 2100509. (2021).
22. Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* **593**, 270–274 (2021).
23. Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **372**, n579 (2021).
24. Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A.* **117**, 7001–7003 (2020).
25. Luo, W. et al. Circulating levels of IL-2, IL-4, TNF-α, IFN-γ, and C-reactive protein are not associated with severity of COVID-19 symptoms. *J. Med. Virol.* **93**, 89–91 (2021).

26. Nie, X. et al. Multi-organ proteomic landscape of COVID-19 autopsies. *Cell* **184**, 775-791.e14 (2021)

27. Cugno, M. et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. *J. Autoimmun.* **116**, 102560 (2021).

28. Cugno, M. et al. Complement activation in patients with COVID-19: A novel therapeutic target. *J. Allergy Clin. Immunol.* **146**, 215–217 (2020).

29. Ishimi, Y. Regulation of MCM2-7 function. *Genes Genet. Syst.* **93**, 125–133 (2018).

30. Sha, H. et al. Modulation of 17β-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors. *International Immunopharmacology* **7**, 1765–75 (2007).

31. Luo, C. T. et al. Ets transcription factor GABP controls T cell homeostasis and immunity. *Nat. Commun.* **8**, 1062 (2017).

32. Madri, J. A. & Furthmayr, H. Collagen polymorphism in the lung: An immunochemical study of pulmonary fibrosis. *Hum. Pathol.* **11**, 353–366 (1980).

33. Ball, L. et al. Extension of Collagen Deposition in COVID-19 Post Mortem Lung Samples and Computed Tomography Analysis Findings. *Int. J. Mol. Sci.* **22**, 7498 (2021).

34. Zhang, H. et al. Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. *Ann. Intern. Med.* **172**, 629–632 (2020).

35. Adachi, T. et al. Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan. *Emerg. Infect. Dis. J.* **26**, 2157–2161. (2020)

36. Valenti, L. et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. *J Autoimmun.* **117**, 102595 (2021).

37. Ricklin, D. et al. Complement: a key system for immune surveillance and homeostasis. *Nat. Immunol.* **11**, 785–797 (2010).

38. Joly, B. S. et al. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med.* **46**, 1603–1606 (2020).

39. Mandal, S. K. et al. Cellular localization and trafficking of tissue factor. *Blood* **107**, 4746–4753 (2006).

40. Smith, S. A. et al. How it all starts: Initiation of the clotting cascade. *Crit. Rev. Biochem. Mol. Biol.* **50**, 326–336 (2015).

41. José, R. J. Proteinase-activated receptors in fibroproliferative lung disease. *Thorax* **69**, 190–2 (2013).

42. Morrissey, J. H. et al. Polyphosphate: a link between platelets, coagulation and inflammation. *Int J Hematol* **95**, 346–52 (2012).

43. Morrissey, J. H. et al. A. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. *Blood* **119**, 5972–5979 (2012).

44. Müller, F. et al. Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo. *Cell* **139**, 1143–1156 (2009).
45. Hess, R. et al. Coagulation factor XII regulates inflammatory responses in human lungs. *Thromb. Haemost.* **117**, 1896–1907 (2017).

46. Golias, C. et al. A. The kinin system - bradykinin: biological effects and clinical implications. Multiple role of the kinin system - bradykinin. *Hippokratia* **11**, 124–128 (2007).

47. Subramanian Vignesh, K. et al. Metallothioneins: Emerging Modulators in Immunity and Infection. *Int. J. Mol. Sci.* **18**, 2197 (2017).

48. Kavitha Subramanian, V. et al. Granulocyte Macrophage-Colony Stimulating Factor Induced Zn Sequestration Enhances Macrophage Superoxide and Limits Intracellular Pathogen Survival. *Immunity* **39**, 697–710 (2013).

49. Pan, P. et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. *Nat Commun.* **12**, 4664 (2021).

50. Nuñez, I. A. et al. SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection. *mSphere* **6**, e00507-21 (2021).

51. Imai, M. et al. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. *Proc Natl Acad Sci U S A* **118**, e2106535118. (2021).

52. Abdelnabi, R. et al. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. *J. Infect. Dis.* **224**, 749–753 (2021).

53. Abdelnabi, R. et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. *EBioMedicine* **68**, 103403 (2021).

54. Munster, V. J. et al. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. *bioRxiv* 2021.05.07.443115 (2021).

55. Horspool, A. M. et al. SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern induce lethal disease in K18-hACE2 transgenic mice despite convalescent plasma therapy. *bioRxiv* 2021.05.05.442784 (2021).

56. Radvak, P. et al. B.1.1.7 and B.1.351 variants are highly virulent in K18-ACE2 transgenic mice and show different pathogenic patterns from early SARS-CoV-2 strains. *bioRxiv* 2021.06.05.447221 (2021).

57. Song, E. et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med* **218**, e20202135 (2021).

58. Kumari, P. et al. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. *Viruses* **13**, 132 (2021).

59. Heinrich, F. et al. Dying of VOC-202012/01 — multimodal investigations in a death case of the SARS-CoV-2 variant. *Int. J. Legal Med.* **5**, 1–10 (2021).

60. Santana, M. F. et al. Hemorrhagic and thrombotic manifestations in the central nervous system in COVID-19: A large observational study in the Brazilian Amazon with a complete autopsy series. *PLOS ONE* **16**, e0255950 (2021).
61. Chiyo, T. *et al.* Conditional gene expression in hepatitis C virus transgenic mice without induction of severe liver injury using a non-inflammatory Cre-expressing adenovirus. *Virus Res.* **160**, 89–97 (2011).

62. Ishigaki, H. *et al.* Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques. *Virology* **554**, 97–105 (2021).

**Figures**
Figure 1

Development of a severe pneumonia mouse model following SARS-CoV-2 infection transduced with rAd5 pEF1α-hACE2-L

(a) Schematic diagram of rAd5 pEF1α-hACE2-L. ITR indicates an inverted terminal repeat. Δ E1 and Δ E3 indicate the deletion of E1 and E3 genes from the adenoviral genome. (b) Changes in body weight of rAd5
pEF1α-hACE2-L-infected BALB/C mice. Data represent means and standard deviations (SD), n=18. (c) Changes in body weight of SARS-CoV-2 (Wu-2020, 1´10^5 PFU/animal)-infected BALB/c mice. Day 0 equals 5 dpi of rAd5 pEF1α-hACE2-L at the indicated FFU/mouse. Data represent means and SD, n=6. (d) Changes in body weight of SARS-CoV-2 Wu-2020-inoculated BALB/c mice at the indicated PFU/mouse. Day 0 equals 5 dpi of rAd5 pEF1α-hACE2-L (5´10^7 FFU/animal). Data represent means and SD, n=6. (e) Lung macroscopic appearance and histopathologic findings with HE staining of the lungs at 7 dpi. Scale bars represent 20 µm.
Figure 2

Comparison of pathogenesis of SARS-CoV-2 variants in the mouse model

(a) Viral growth in Vero E6/TMPRSS2 cells at an MOI of 0.001. Viral titers are shown in PFU/mL, which were calculated by a standard plaque assay using Vero E6/TMPRSS2 cells. Data represent means and SD, n=3. (b) Viral loads in lung homogenate determined by qRT-PCR to detect the SARS-CoV-2 genome.
**c)** Viral titers in lung homogenate determined by a plaque assay using Vero E6/TMPRSS2 cells. Data represent means and SD, \( n=5 \) (2d and 4d) and \( n=6 \) (7d). *\( p<0.05 \), **\( p<0.01 \). The colors of the asterisks indicate the following: black (vs Wu-2020) and pink (vs B.1.1.5). **d)** Macroscopic appearance of lung. Yellow arrows indicate lesions with a dark red and brown color. **e)** Changes in body weight of SARS-CoV-2 variant-infected BALB/c mice. Day 0 equals 5 dpi of rAd5 pEF1α-hACE2-L (5′10^7 FFU/animal). The p value is shown (Wu-2020 vs mock and all VOCs). Data represent means and SD, \( n=6 \).
Figure 3

Histopathological analyses and cytokine levels of mouse lung infected with SARS-CoV-2 variants

(a) Histopathologic findings with HE staining and detection of SARS-CoV-2 N protein in mouse lungs (left lobe) infected with SARS-CoV-2. (b) Left lung homogenates were used for measurement of multiplex cytokines and chemokines using the Bio-plex suspension array system. Data represent means and SD, n=5. *p<0.05, **p<0.01. The colors of the asterisks indicate the following: black (vs mock) and gray (vs Wu-2020).
Figure 4

Proteomic landscape of SARS-CoV-2 infected mouse lungs

(a) Volcano plots for mouse lung proteome of the indicated group compared adenovirus-infected/SARS-CoV-2 non-infected (mock) mice. Up-regulated ($\log_2 \geq 1$) and down-regulated ($\log_2 \leq -1$) proteins and $p$ value $< 0.05$ indicate threshold lines. The numbers of up- and down-regulated proteins are 403 and 411
(Wu-2020 vs Mock), 206 and 289 (B.1.1.7 vs Mock), 283 and 236 (P.1 vs Mock), 249 and 189 (B.1.351 vs Mock). (b) GO enrichment analysis in proteomes of SARS-CoV-2-infected mouse lungs. Top 20 terms of each group are shown. Terms were further categorized in immune response (orange), blood system (pink), DNA replication (green) and structure organization (blue). (c-g) Intrinsic relative protein expressions categorized in regulation of immune effector process (c), platelet degranulation (d), extracellular structure organization (e), regulation of blood coagulation (f) and nuclear DNA replication (g). Relative values (mock = 1) were shown. The dashed lines represent the thresholds of up-regulation (>2) and down-regulation (<0.5).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- 5.tif
- 6.tif
- 7.tif
- 8.tif